Tuberculosis

Introducing fast and accurate tests where patients seek care

 

Malaria & Acute febrile syndrome (AFS)

Assuring quality of existing rapid tests and developing new tools

Neglected tropical diseases (NTDs)

Contributing to elimination through new and improved tests

Ebola

Partnering to deliver the right tools to the right places

Access

Laboratory strengthening and training

  • 1
  • 2
  • 3
  • 4
  • 5

Latest News

World’s most portable molecular diagnostics system unveiled at AACC

28 July 2015

SUNNYVALE, CALIFORNIA & GENEVA, SWITZERLAND —July 28, 2015 — Cepheid (Nasdaq: CPHD) and FIND today unveiled the GeneXpert® Omni, the world’s most portable molecular diagnostics system enabling unprecedented access to accurate, fast and potentially life-saving diagnosis for patients suspected of having TB, HIV and Ebola in even the most remote areas of the world.

FIND and QIAGEN intensify partnership to accelerate innovative TB tests

28 July 2015

FIND and QIAGEN have signed a five-year memorandum of understanding to formalize their partnership to advance diagnostics for tuberculosis. The partnership spans three areas: tests to enable targeted preventive therapy, tests to detect drug resistance at the point of care, and sequencing as a future gold standard in TB surveillance and regimen selection.

Message from the CEO on World Hepatitis Day 2015

28 July 2015

At this very moment, 400 million people are living with hepatitis B or C. And this year, 1.4 million will die as a result. On World Hepatitis Day and every day, we at FIND are reminded anew of how shocking these numbers are, how unacceptable – and how unnecessary.

High-priority TPP for hepatitis C diagnosis in decentralized settings: Report of a consensus meeting

17 July 2015

FIND and the Forum for Collaborative HIV Research have released a report containing the results of a consensus meeting on target product profiles for high-priority hepatitis C diagnosis in decentralized settings.

right column